Fig. 6

UNC0379 sensitizes cancer cells to cisplatin treatmentin vitro and in vivo. (A-B) dose-response curves for UNC0379 or cisplatin alone or combined in SiHa and CaSki cells treated with varying concentrations of UNC0379 (0–8 µM) and cisplatin (0–24 µM) with constant ratio of 1:3 when combined for 48 h. (C-D) Colony formation assays were performed using SiHa and CaSki cells with UNC0379 and cisplatin treatment. (E) Tumor growth of UNC0379- and cisplatin-treated mice carrying SiHa cell xenografts. Error bars represent SEM. (F) Size comparisons for tumors from each treatment group. Scale bar represents 10 mm. (G) Tumor weight for each group, p values were determined by unpaired Student’s t test; error bars represent SD. (H) SETD8 IHC staining of subcutaneous tumors of each group at the experimental endpoint. Images were taken at a magnification of 100× and 400×. Scale bars represent 10 μm. (I) γ-H2AX IHC staining at the experimental endpoint. Images were taken at a magnification of 100× and 400×. Scale bars represent 10 μm